IL-2 therapy has been used to increase the per capita growth rate of T cells in vivo and is the key driver of ex vivo expansion of tumor infiltrating lymphocytes (TIL) used for TIL-based immunotherapy in cancer (82, 83). This evidence concerns the gene IL2 and neoplasm.